You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股异动 | 凯普生物(300639.SZ)涨超6% 上半年净利润同比预增148.09%-186.85%
格隆汇 05-31 14:16
格隆汇5月31日丨凯普生物(300639.SZ)现报32.16元,涨6.28%,暂成交4.66亿元,最新市值94.5亿元。凯普生物5月27日盘后发公告称,预计2021年上半年公司实现归属于上市公司股东的净利润为盈利3.2亿元-3.7亿元,同比增长148.09%-186.85%。公司医学实验室(含香港)积极参与疫情防控和加强能力建设,检测服务收入取得快速增长,核酸检测需求增加对公司主要产品及配套仪器、耗材带来销售拉动。报告期内,公司主营业务收入取得快速增长,带动公司业绩快速增长。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account